PL2442832T3 - Kompozycje i sposoby do leczenia stwardnienia rozsianego - Google Patents
Kompozycje i sposoby do leczenia stwardnienia rozsianegoInfo
- Publication number
- PL2442832T3 PL2442832T3 PL10789788T PL10789788T PL2442832T3 PL 2442832 T3 PL2442832 T3 PL 2442832T3 PL 10789788 T PL10789788 T PL 10789788T PL 10789788 T PL10789788 T PL 10789788T PL 2442832 T3 PL2442832 T3 PL 2442832T3
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- treatment
- methods
- multiple sclerosis
- sclerosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Fodder In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Photographic Developing Apparatuses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ577731A NZ577731A (en) | 2009-06-16 | 2009-06-16 | Compositions and methods for treatment of multiple sclerosis |
| EP10789788.6A EP2442832B1 (en) | 2009-06-16 | 2010-06-16 | Compositions and methods for treatment of multiple sclerosis |
| PCT/NZ2010/000112 WO2010147484A1 (en) | 2009-06-16 | 2010-06-16 | Compositions and methods for treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2442832T3 true PL2442832T3 (pl) | 2015-01-30 |
Family
ID=42646236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10789788T PL2442832T3 (pl) | 2009-06-16 | 2010-06-16 | Kompozycje i sposoby do leczenia stwardnienia rozsianego |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8389479B2 (enExample) |
| EP (1) | EP2442832B1 (enExample) |
| JP (1) | JP5646617B2 (enExample) |
| CN (1) | CN102458476B (enExample) |
| AU (1) | AU2010260585B2 (enExample) |
| BR (1) | BRPI1009606A2 (enExample) |
| CA (1) | CA2688766C (enExample) |
| CY (1) | CY1115714T1 (enExample) |
| DK (1) | DK2442832T3 (enExample) |
| ES (1) | ES2521565T3 (enExample) |
| HR (1) | HRP20141035T1 (enExample) |
| IL (1) | IL216993A (enExample) |
| IN (1) | IN2012DN00167A (enExample) |
| MX (1) | MX2011013661A (enExample) |
| NZ (1) | NZ577731A (enExample) |
| PL (1) | PL2442832T3 (enExample) |
| PT (1) | PT2442832E (enExample) |
| SI (1) | SI2442832T1 (enExample) |
| SM (1) | SMT201400165B (enExample) |
| WO (1) | WO2010147484A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103990120B (zh) * | 2008-04-01 | 2018-06-05 | 伊耐特免疫治疗有限公司 | 抗感染剂及其用途 |
| EP3722808B1 (en) * | 2010-10-25 | 2024-09-11 | Biogen MA Inc. | Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels |
| UY35790A (es) * | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| CA2926507A1 (en) * | 2015-10-06 | 2017-04-06 | Innate Immunotherapeutics Limited | Compositions and methods for protection and/or repair of the nervous system |
| WO2017059486A1 (en) * | 2015-10-06 | 2017-04-13 | Innate Immunotherapeutics Limited | Compositions and methods for the treatment of epilepsy |
| WO2017070731A1 (en) * | 2015-10-28 | 2017-05-04 | Innate Immunotherapeutics Limited | Compositions and methods for the treatment of alzheimer's disease |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| AU2017319728B2 (en) | 2016-08-31 | 2024-09-05 | Mapi Pharma Ltd | Depot systems comprising glatiramer acetate |
| IL316573A (en) | 2017-03-26 | 2024-12-01 | Mapi Pharma Ltd | Storage systems containing glatiramer acetate for the treatment of multiple sclerosis |
| WO2019218079A1 (en) * | 2018-05-18 | 2019-11-21 | Universite Laval | Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer's disease |
| WO2020010221A1 (en) * | 2018-07-03 | 2020-01-09 | University Of Florida Research Foundation, Inc. | Microparticle systems and their use for the treatment of multiple sclerosis |
| BR112022024966A2 (pt) * | 2020-06-22 | 2023-01-03 | Otivio As | Métodos para tratar espasticidade usando composições antiespasmódicas e terapia de pressão negativa |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU732809B2 (en) * | 1996-10-10 | 2001-05-03 | Innate Immunotherapeutics Limited | Compositions and methods for treating viral infections |
| EA200700263A1 (ru) * | 2004-07-01 | 2007-06-29 | Кебенхавнс Университет | Способ лечения и профилактики рассеянного склероза путём лечения лептоспирозной инфекции |
| WO2008070564A1 (en) | 2006-12-01 | 2008-06-12 | The Government Of The U.S.A, As Represented By The Secretary, Departmentof Health And Human Services | Uses of muramyl dipeptide (mdp) for treating inflammation |
| JP2008251608A (ja) | 2007-03-29 | 2008-10-16 | Casio Comput Co Ltd | 半導体装置およびその製造方法 |
| WO2008150182A1 (en) | 2007-06-05 | 2008-12-11 | Innate Therapeutics Limited | Compositions and methods for treatment of anthrax |
| WO2008150181A1 (en) | 2007-06-05 | 2008-12-11 | Innate Therapeutics Limited | Compositions and methods for treating anthrax exposure associated conditions |
-
2009
- 2009-06-16 NZ NZ577731A patent/NZ577731A/en not_active IP Right Cessation
- 2009-12-16 US US12/639,733 patent/US8389479B2/en not_active Expired - Fee Related
- 2009-12-17 CA CA2688766A patent/CA2688766C/en not_active Expired - Fee Related
-
2010
- 2010-01-16 CN CN201080026791.5A patent/CN102458476B/zh not_active Expired - Fee Related
- 2010-01-16 BR BRPI1009606A patent/BRPI1009606A2/pt not_active Application Discontinuation
- 2010-06-16 EP EP10789788.6A patent/EP2442832B1/en active Active
- 2010-06-16 AU AU2010260585A patent/AU2010260585B2/en not_active Ceased
- 2010-06-16 IN IN167DEN2012 patent/IN2012DN00167A/en unknown
- 2010-06-16 PL PL10789788T patent/PL2442832T3/pl unknown
- 2010-06-16 MX MX2011013661A patent/MX2011013661A/es active IP Right Grant
- 2010-06-16 ES ES10789788.6T patent/ES2521565T3/es active Active
- 2010-06-16 HR HRP20141035AT patent/HRP20141035T1/hr unknown
- 2010-06-16 WO PCT/NZ2010/000112 patent/WO2010147484A1/en not_active Ceased
- 2010-06-16 JP JP2012516022A patent/JP5646617B2/ja not_active Expired - Fee Related
- 2010-06-16 DK DK10789788.6T patent/DK2442832T3/da active
- 2010-06-16 PT PT107897886T patent/PT2442832E/pt unknown
- 2010-06-16 SI SI201030779T patent/SI2442832T1/sl unknown
-
2011
- 2011-12-15 IL IL216993A patent/IL216993A/en not_active IP Right Cessation
-
2014
- 2014-11-03 CY CY20141100908T patent/CY1115714T1/el unknown
- 2014-11-04 SM SM201400165T patent/SMT201400165B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010147484A1 (en) | 2010-12-23 |
| AU2010260585B2 (en) | 2013-02-21 |
| CY1115714T1 (el) | 2017-01-25 |
| JP5646617B2 (ja) | 2014-12-24 |
| ES2521565T3 (es) | 2014-11-12 |
| US20100317589A1 (en) | 2010-12-16 |
| IN2012DN00167A (enExample) | 2015-04-17 |
| AU2010260585A1 (en) | 2012-01-19 |
| EP2442832A1 (en) | 2012-04-25 |
| EP2442832A4 (en) | 2013-07-03 |
| US8389479B2 (en) | 2013-03-05 |
| SI2442832T1 (sl) | 2014-12-31 |
| JP2012530132A (ja) | 2012-11-29 |
| SMT201400165B (it) | 2015-01-15 |
| WO2010147484A8 (en) | 2012-07-19 |
| HK1167101A1 (en) | 2013-02-01 |
| BRPI1009606A2 (pt) | 2016-10-11 |
| CN102458476A (zh) | 2012-05-16 |
| EP2442832B1 (en) | 2014-08-06 |
| PT2442832E (pt) | 2014-11-11 |
| CA2688766C (en) | 2015-06-30 |
| DK2442832T3 (da) | 2014-11-10 |
| AU2010260585A8 (en) | 2012-06-14 |
| HRP20141035T1 (hr) | 2014-12-19 |
| IL216993A0 (en) | 2012-02-29 |
| CN102458476B (zh) | 2014-08-20 |
| MX2011013661A (es) | 2012-05-22 |
| CA2688766A1 (en) | 2010-12-16 |
| IL216993A (en) | 2016-03-31 |
| NZ577731A (en) | 2010-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267014A (en) | Preparations and methods for the treatment of autoimmune diseases and other diseases | |
| IL252699A0 (en) | Use of lequinimod to treat multiple sclerosis | |
| IL216993A0 (en) | Compositions and methods for treatment of multiple sclerosis | |
| EP2448581A4 (en) | THERAPEUTIC COMPOSITIONS AND METHODS OF USE THEREOF | |
| EP2655334A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES | |
| EP2429584A4 (en) | TREATMENT PROCEDURE AND COMPOSITIONS | |
| ZA201107789B (en) | Antimicrobial composition and related method of use | |
| EP2771030A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES | |
| IL215592A0 (en) | Compositions and methods for the treatment of inflammation | |
| IL214455A0 (en) | Methods and compositions for treatment of neovascularization | |
| IL218212A0 (en) | Therapeutic methods and compositions | |
| GB201302653D0 (en) | Pharmaceutical compositions and methods of treatment | |
| IL215856A0 (en) | Compositions and methods for treatment of cardiovascular disease | |
| GB0919097D0 (en) | Treatment of hard surfaces | |
| IL214349A0 (en) | Compositions and methods for the treatment of cancer | |
| IL225793A0 (en) | Methods and preparations for curing insulin-related medical conditions | |
| ZA201102207B (en) | Cinnamandehyde-allicin compositions and their method of use | |
| IL217535A0 (en) | Compositions and methods of use for post-radiation protection | |
| EP2405747A4 (en) | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES | |
| IL215054A0 (en) | Compositions and methods for prevention and treatment of neurodegenerative diseases | |
| EP2515652A4 (en) | COMPOSITIONS AND METHODS FOR TREATING VITILIGO | |
| EP2461870A4 (en) | THERAPEUTIC COMPOSITIONS AND METHOD | |
| EP2381950A4 (en) | COMPOSITIONS AND METHOD FOR THEIR USE | |
| EP2480099A4 (en) | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING METABOLIC DISEASES | |
| EP2563923A4 (en) | COMPOSITIONS AND METHODS FOR REDUCING SCARS AND TREATING FIBROSIS |